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ORIGINAL ARTICLE
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ABSTRACT
Bone pain is a serious and debilitating symptom of multiple myeloma (MM) that impairs the quality of life of patients. The underlying
mechanisms of the pain are unknown and understudied, and there is a need for immunocompetent preclinical models of myeloma-
induced bone pain. The aim of this study was to provide the first in-depth behavioral characterization of an immunocompetent
mouse model of MM presenting the clinical disease features: osteolytic bone disease and bone pain. We hypothesized that a widely
used syngeneic model of MM, established by systemic inoculation of green fluorescent protein-tagged myeloma cells (5TGM1-GFP)
in immunocompetent C57Bl/KaLwRijHsd (BKAL) mice, would present pain-related behaviors. Disease phenotype was confirmed by
splenomegaly, high serum paraprotein, and tumor infiltration in the bonemarrow of the hind limbs; however, myeloma-bearingmice
did not present pain-related behaviors or substantial bone disease. Thus, we investigated an alternative model in which 5TGM1-GFP
cells were directly inoculated into the intrafemoral medullary cavity. This localized myeloma model presented the hallmarks of the
disease, including high serum paraprotein, tumor growth, and osteolytic bone lesions. Compared with control mice, myeloma-
bearing mice presented myeloma-induced pain-related behaviors, a phenotype that was reversed by systemic morphine treatment.
Micro-computed tomography analyses of the myeloma-inoculated femurs showed bone disease in cortical and trabecular bone.
Repeated systemic bisphosphonate treatment induced an amelioration of the nociceptive phenotype, but did not completely reverse
it. Furthermore, intrafemorally injected mice presented a profound denervation of the myeloma-bearing bones, a previously
unknown feature of the disease. This study reports the intrafemoral inoculation of 5TGM1-GFP cells as a robust immunocompetent
model of myeloma-induced bone pain, with consistent bone loss. Moreover, the data suggest that myeloma-induced bone pain is
caused by a combinatorial mechanism including osteolysis and bone marrow denervation. © 2019 The Authors. JBMR Plus published
by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
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Introduction
M ultiple myeloma (MM) is a largely incurable neoplasia ofplasma cells with an incidence of six people in a popula-
tion of 100,000 per year in Europe.(1) Approximately 90% of
MM patients develop bone disease,(2) which is characterized by
an imbalance in the bone remodeling process that leads to the
development of purely osteolytic lesions. Often these lesions
induce hypercalcemia,(3) pathological fractures,(4) and spinal
cord compression,(5) and are associated with decreased survival
expectancy.(6)
The commonest symptom of MM is bone pain, which affects
70% of myeloma patients,(7–10) and up to 90% in the advanced
stages of the disease.(11) Myeloma-induced bone pain is often
described as severe, and it impairs the patient’s quality of life.(12)
As the survival expectancy has been reported to increase thanks
to the development of new therapies for the disease
treatment,(13) novel analgesic avenues for the treatment of bone
pain in myeloma patients are called for. Surprisingly, little is
known about the characteristics and underlying mechanisms of
myeloma-induced bone pain.
Although several preclinical models of MM have been devel-
oped over the years with the goal of understanding disease
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etiology and identifying novel drug targets, only one xenograft
mouse model of MM has been evaluated in terms of myeloma-
induced bone pain.(14) Xenograft models, however, rely on the
use of immunosuppressed mice, whereas MM is a plasma cell
cancer and mounting evidence suggests that the immune sys-
tem plays a pivotal role in chronic pain development.(15–18) Thus,
there is a clear need for a superior model of myeloma-induced
bone pain that integrates the immune component.
To address this, we studied pain-related behaviors in a com-
monly used syngeneic model of MM, in which a subclone of
myeloma cells (5TGM1) is propagated by tail vein injection in
C57BL/KaLwRijHsd (BKAL) mice.(19) We found that these mice
display a phenotype consistent with MM, including high serum
paraprotein, tumor growth in the bone marrow, and
splenomegaly,(19,20) but did not present bone loss or a pain-like
phenotype. Consequently, we investigated pain-related behav-
iors in a variant of this model in which 5TGM1 cells are intrafemo-
rally inoculated, and show that these mice present high serum
paraprotein, pain-like behaviors, significant bone destruction,
and alterations in the distribution of sympathetic and sensory
neurons innervating the hind limb bones. This localized, synge-
neic model of MM is a powerful and clinically relevant tool to
understand myeloma-induced bone pain.
Materials and Methods
Cell culture
Green fluorescent protein- (GFP-) tagged 5TGM1 cells(21) were
maintained by serial passage and cultured in vitro for less than
10 days(22,23) in Roswell Park Memorial Institute media with glu-
tamine and phenol red, supplemented with 10% FBS, 1%
penicillin–streptomycin (100 U/100 μg/mL), 1% sodium pyru-
vate (1mM), and 1% MEM nonessential amino acids (1X) at
37C in 5% CO2.
Animals
Animal experiments were approved by the Danish Animal Exper-
iments Inspectorate (Copenhagen, Denmark) and performed
according to the Danish Act on Animal Experiments (LBK
No. 474 of 15/05/2014) and in compliance with the Guide for
the Care and Use of Laboratory Animals: Eighth Edition (National
Academies Press, Washington, DC, USA; 2011). Sixty-five 4- to
5-week-old male BKAL mice (Envigo, Venray, Netherlands) were
housed in groups of four or five in individually ventilated
GM500+ cages (524 cm2), with standard diet (Altromin 1314; Bro-
gaarden, Gentofte, Hovedstaden, Denmark) and tap water ad
libitum, in a temperature-controlled room (21C to 24C) on a
12-hour light/dark cycle. Cages contained Tapvei 2 HV bedding
(Brogaarden) and environmental enrichment: S-brick (Tapvei,
Paekna, Estonia), red translucent shelter, paper ropes, and corn
hidden in the bedding. Mice were randomized into sham or
myeloma-bearing groups according to weight or burrowing
capacity. General health, including body weight, coat condition,
and abnormal behaviors, was regularly assessed.
Animal models
The systemic model of MM was generated by i.v. injection of
5TGM1-GFP cells (2 × 106/100 μL; n = 24) or vehicle (saline;
n = 25) into the tail veins of 5- to 6-week-old awake BKAL mice;
in the localized model, 5TGM1-GFP cells (5 × 104/10 μL; n = 29)
or vehicle (saline; n = 16) were inoculated in the intramedullary
femoral cavity, as previously described in models of cancer-
induced bone pain.(24) Briefly, 5- or 6-week-old mice were rapidly
anesthetized with 4% isoflurane (Nomeco, Copenhagen, Den-
mark), and thereafter administered an i.p. cocktail of ketamine/
xylazine [85.5 mg/kg ketamine from Ketaminol vet (MSD Animal
Health, AN Boxmeer, The Netherlands) and 12.5 mg/kg xylazine
from Nerfasin vet (Virbac, Kolding, Denmark)]. Full anesthesia
was confirmed by loss of pedal reflex; eye ointment (Ophta A/
S, Actavis Group, Gentofte, Denmark) was applied and themouse
was placed on a heating pad on the dorsal side; the right anterior
knee was shaved and disinfected with 70% ethanol. An incision
(<10 mm) was made on the superficial skin covering the patella,
the retinaculum tendon was loosened and the patella displaced,
exposing the distal femoral epiphysis. A 30G needle was used to
drill a hole into the epiphysis, and then an insulin needle (0.3 mL;
BD Rowa Technologies [BD], Lyngby, Denmark) was inserted.
Vehicle (10 μL PBS) or 5 × 104 5TGM1-GFP cells/10 μL PBS were
injected into the femoral intramedullary cavity. The hole was
closed with Ethicon bone wax (Mediq Danmark A/S, Brøndy,
Denmark), and the patella was carefully pushed into place. The
wound was irrigated with saline and closed with two surgical
clips (7.50 × 1.75 mm; Agnthos, Lidingö, Sweden). Mice received
s.c. administration of 500 μL saline and 0.03 mg/kg buprenor-
phine (Temgesic; Indivior UK Limited, Slough, UK), and xylocaine
gel (2%w/v, Nomeco) was applied on the surgical site. Mice were
randomized into sham or myeloma-bearing groups according to
weight or burrowing performance.
Behavioral testing
All behavioral tests were performed by the same researchers,
who were blinded to the experimental groups/conditions,
between 8:00 a.m. and 2:00 p.m.
Stimulus-evoked behavioral tests
von Frey test
Mechanical hypersensitivity was assessed with von Frey fila-
ments following the Dixon up-and-down method(25) to calculate
the 50% paw withdrawal threshold as defined by Chaplan and
colleagues.(26,27) Briefly, mice were acclimatized to individual
chambers (90 × 90 × 120 mm), placed on an elevated wire grid
for 30 to 60 min, and von Frey monofilaments (North Coast
Touch Test; North Coast Medical, Inc., Morgan Hill, CA, USA)
applied perpendicularly on the plantar surface of the right hind
paw for 3 s. Every animal was tested in a range between 0.04
and 4.00g, with a starting point of 0.60g; increasing forces were
used if a negative response was recorded, whereas decreasing
forces were used following a positive response. Positive
responses were defined as clear withdrawal of the limb following
exposure to a filament. Animals were subjected to two training
(including chamber acclimation and random poking) and two
baseline sessions.
Hot plate test
Thermal hyperalgesia was evaluated on a Hot Plate Analgesia
Meter (Harvard Apparatus, Holliston, MA, USA) set at
52.5  0.1C, by quantifying the time lapse between animal
exposure to the apparatus and a positive response. Positive
responses were defined as jumping and licking or flinching of
either hind paw (systemicmodel) or the right hind paw (localized
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model); as previously described,(28) a cut-off of 40 s was estab-
lished to avoid tissue damage.
Non-stimulus-evoked behavioral tests
Burrowing
Burrowing capacity was assessed as previously described,(29) by
individually exposing the mice to burrowing tubes (200 mm
length × 72 mm diameter, raised 30 mm from the ground in
the frontal part) filled with 500 g sand (0–3 mm diameter, Scan-
Sand, Herlev, Denmark) placed in standard plastic cages without
bedding (125 × 66 × 185 mm). Initially, mice were habituated to
the apparatus by placing them in pairs in a box with an empty
burrowing tube. On the second and third training days, mice
were again placed in pairs with the same burrowing tube, filled
with 500-g sand. Two baseline testing sessions were conducted
in the following days by placing the mice individually within a
burrowing tube filled with 500-g sand and the amount of sand
left in the tube was weighed after each session. Thereafter, the
same setup was used on testing days. Burrowing performance
was calculated as 500 g minus the amount of sand left in the
tube (g) at the end of the burrowing session; all burrowing ses-
sions lasted 2 hours.
Locomotor activity
Locomotor activity of freely walkingmice was individually measured
in standard plastic cages without bedding (125 × 266 × 185 mm)
with the tracking software Ethovision XT 8.5 (Noldus Information
Technology,Wageningen, TheNetherlands); initially,micewere accli-
matized for 15 min, and the speed and distance walked for the fol-
lowing 15 min were calculated.
Limb use
Limb use was evaluated as previously described(30) by observing
the mice freely walking in standard plastic cages
(125 × 266 × 185 mm) without bedding for 3 min after 10-min
acclimation. The scoring was: 4 = normal gait, 3 = insignificant
limping, 2 = significant limping accompanied by a shift in body
distribution towards the healthy limb, 1 = significant limping
and partial paraplegia, 0 = paraplegia (defined as humane
endpoint).
Morphine validation experiment
On postsurgical day 26, the limb use score of all animals was
assessed. Thereafter, i.p. saline (100 μL) was administered to all
mice and limb use was assessed after 30, 60, and 120 min. Mice
were returned to their cages for 4 hours, and their limb use
was assessed again. Then, all animals received 10 mg/kg−1 mor-
phine(30) (morphine hydrochloride; Skanderborg Produktionsa-
potek, Copenhagen, Denmark), dissolved in i.p. saline (100 μL)
and their gait was evaluated after 30, 60, and 120 min. To avoid
a ceiling effect, myeloma-bearing animals with a limb use score
of 4 on day 26 were excluded, as a score of 4 in the limb use test
indicates the absence of a pain-like phenotype, and therefore the
lack of a therapeutic window (n = 3); similarly, myeloma-bearing
mice with a limb use score ≤1, which could be indicative of motor
impairment caused by paraplegia development, were also
excluded (n = 2). Experimenters were completely blinded to the
study design, and the exclusion parameters were carried out by a
different researcher than the one performing all behavioral tests.
Bisphosphonate experiment
Mice were treated biweekly with vehicle (sham n = 4 and MM
n = 8) or zoledronic acid (125 μg/kg−1, Procter and Gamble Phar-
maceuticals, Mason, OH, USA; n = 7), administered s.c. in a vol-
ume of 100 μL, as previously described.(31) Treatment started
3 days after tumor inoculation and lasted for the duration of
the experiment. Animals were randomized according to weight
into the different treatment groups. All dosing and behavioral
testing was conducted by an experimenter blinded to the exper-
imental groups and treatments.
Euthanasia and tissue analyses
Mice were euthanized by cervical dislocation, the spleens
weighed, and tibias and femurs excised. The joints were cut,
and the bone marrows extruded with 500-μL PBS through a
27G needle. Blood cells were lysed with the Human Erythrocyte
Lysing Kit (R&D Systems, Minneapolis, MN, USA) following the
manufacturer’s recommendations; the resulting cell suspension
was imaged in a ZOE Fluorescent Cell Imager (Bio-Rad Laborato-
ries, Hercules, CA, USA). Cells were automatically quantified with
ImageJ software (NIH, Bethesda, MD, USA; https://imagej.nih.
gov/ij/) and the percentage of GFP-positive cells calculated as
the average of three pictures.
Alternatively, mice were transcardially perfused with ice-cold
PBS and 25 to 30 mL of 4% paraformaldehyde (Merck, Søborg,
Denmark). Hind limb bones were postfixated in 4% paraformal-
dehyde at 4C for 24 hours and stored in 0.1M PBS or 70% etha-
nol at 4C.
Determination of serum levels of paraprotein by ELISA
Serum samples were obtained by cardiac puncture at euthana-
sia. The serum IgG2b paraprotein content was assessed in an
ELISA kit (Cat# E99-109; Bethyl Laboratories, Inc., Mountain View,
CA, USA) following manufacturer’s recommendations.
Micro-computed tomography (μCT) analyses
μCT scanning and lesion analyses were performed using a Sky-
Scan 1272 Desktop X-Ray Tomographer (SkyScan, Aartselaar, Bel-
gium) as previously described.(31) Bone disease was assessed by
μCT measuring of osteolytic lesion area (%), trabecular bone vol-
ume (% BV/TV), trabecular thickness (Tb. Th), and trabecular
number (Tb. N) using a SkyScan 1272 Desktop X-Ray Tomogra-
pher with a medium-sized 2000 × 1048 pixel camera and an
X-ray source powered by 50 kV and 200 μA electric current.
Low-energy radiations were filtered with a 0.5-mm aluminum fil-
ter. The proximal end of the tibia or distal femur was scanned at
4.3-μm pixels for every 0.7-degree rotation of 180 degrees. The
scanned images were reconstructed using NRecon software (ver-
sion 1.6.1.1; SkyScan) within a dynamic range of 0 to 0.14 and a
ring artifact reduction factor of 1%. The reconstructed images
were analyzed using CTAn (version 1.9.1.1 Bruker, Belgium).
Analysis were done on the cross-sectional images of the tibias
or femurs at a distance of 1.2 mm (offset) from the distal break
in the growth plate (reference point), on a fixed 1-mm region.
The trabecular bone was carefully traced on all cross-sectional
images of the tibia, not to include cortical bone for the entire
ROI. Analyses were done in batches using BatMan (Batch Man-
ager Bruker, Belgium) software; for trabecular analysis, the binar-
ized images were thresholded between 90 to 255.
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Immunohistochemistry and laser confocal microscopy
Femurs were gently decalcified in 10% EDTA for approximately
2 weeks at 4C; decalcification was monitored radiographically to
ensure minimum EDTA exposure and maximum immunohisto-
chemical antigenicity. Next, femurs were cryoprotected in 30%
sucrose for 48 hours and serially sectioned in a cryostat along the
longitudinal axis at a thickness of 20 μm. Sections were blocked
(3% normal donkey serum, 0.3% triton X-100) for 1 hour and incu-
bated with a cocktail of anti-GFP antibody (polyclonal chicken anti-
GFP, 1:2000; Cat #A10262; Thermo Fisher Scientific, Rockford, IL,
USA) and antibodies against calcitonin-gene-related peptide
(CGRP; polyclonal rabbit anti-rat CGRP, conjugated to keyhole limpet
hemocyanin(32–34) 1:5000; #C8198; Sigma-Aldrich, St. Louis, MO,
USA), growth-associated protein-43 (GAP43; rabbit anti-GAP43;
#AB5220; Millipore, Billerica, MA, USA), or tyrosine hydroxylase (TH;
polyclonal rabbit anti-rat TH, 1:1000; #AB152; Chemicon, Billerica,
MA, USA). Preparations were washed three times in PBS, incubated
with a cocktail of Cy2/Cy3 secondary antibodies (1:400/1:600;
Jackson ImmunoResearch, West Grove, PA, USA) for 3 hours,
washed with PBS three times, counterstained with 40, 6-diamidino-
2-phenyl-indole, dihydrochloride (DAPI; 1:30,000; Molecular Probes,
Eugene, OR, USA) for 5 min, and washed with PBS.
Tissue was dehydrated through an alcohol gradient (70%, 80%,
90%, and 100%), cleared in xylene, coverslipped with di-n-
butylphthalate-polystyrene-xylene (Sigma-Aldrich) and allowed
to dry at room temperature for 12 hours. Sections were imaged
in a scanning confocal laser microscope (Carl Zeiss, model
LSM800; Jena, Germany). Sequential acquisition mode was used
to reduce bleed-through from fluorophores.
Statistical analyses
Data were analyzed in GraphPad Prism 7.0 (GraphPad Inc., La Jolla,
CA, USA) or SAS 9.4 (SAS Institute, Inc., Cary, NC, USA). The experi-
mental unit was a single animal. Sample size was determined
empirically from experience with other models of cancer-induced
pain. Parametric behavioral data were analyzed by two-way
repeated measurements ANOVA with Bonferroni correction; limb
use datawere analyzed by Friedman’s two-way test andWilcoxon’s
two-sample test for single timepoints or by transforming the data
to area under the curve followed by one-way ANOVA and then
Holm-Sidak correction for multiple comparisons. Morphine treat-
ment was analyzed by Friedman’s two-way test and the difference
between morphine-treated and saline-treated animals with Wil-
coxon’s two-sample test for each timepoint. Last measurements
were carried forward, except in the bisphosphonate experiment.
Nonbehavioral datawere analyzed by single ormultiple two-tailed,
unpaired Student’s t tests. All data (except survival percentage) are
presented as mean  SEM. Statistical significance was set at 0.05.
Data-sharing statement
All original protocols used and data reported in this publication
are available upon request. For original data, please contact:
marta.castillo@sund.ku.dk.
Results
Systemic inoculation of myeloma cells does not induce
pain-like behaviors
To assess pain-related behaviors in a widely used syngeneic
model of MM, we inoculated 5TGM1-GFP myeloma cells or
vehicle into the tail vein of BKAL mice (Fig. 1A) and assessed
them in stimulus- and non-stimulus-evoked behavioral tests.
von Frey and hot plate tests (stimulus-evoked tests; Fig. 1B,C)
showed no differences inmechanical allodynia or thermal hyper-
algesia; likewise, no differences in burrowing capacity or locomo-
tor activity (non-stimulus-evoked tests; Fig. 1D–F) were observed
in this mouse model, indicating that myeloma-bearing mice did
not present quantifiable pain-related behaviors.
Systemic inoculation of myeloma cells induces the disease
phenotype, but not osteolytic lesions
The MM phenotype was confirmed by development of paraple-
gia by myeloma-bearing mice, which was defined as a humane
endpoint, approximately 3 to 4 weeks after cell inoculation
(Fig. 1G). To further demonstrate disease development, spleen
weight and the presence of myeloma cells in the bone marrows
were assessed. As expected, microscopic analyses demonstrated
extensive bone marrow invasion by 5TGM1-GFP myeloma cells
(Fig. 2A,B). Moreover, myeloma-bearing mice presented spleno-
megaly, with significantly heavier spleens than their matched
controls (Fig. 2C), as well as increased serum paraprotein
(Fig. 2D).
Although systemic administration of 5TGM1-GFP cells
induced the myeloma-like phenotype, μCT scanning of the long
bones, a common site of myeloma development in patients and
mice,(35,36) showed that myeloma-bearing tibias did not display
significant osteolytic lesions (Fig. 2E,F). As the development of
bone pain has often been associated with the presence of osteo-
lytic lesions,(37,38) these results are consistent with the behavioral
data showing lack of quantifiable pain-related behaviors in this
model.
Intrafemoral inoculation of myeloma cells induces
osteolytic lesions
As the systemic myeloma model did not display pain-like behav-
iors or extensive osteolytic lesions, we investigated a localized
model of MM by administering 5TGM1-GFP cells into the intra-
medullary femoral cavity of BKAL mice (Fig. 3A). Disease pheno-
type was confirmed by significantly increased levels of systemic
serum paraprotein in myeloma-bearing mice, compared with
sham (Fig. 3B). In these animals, μCT analyses of the femurs
showed a threefold increase in the osteolytic lesion area
(Fig. 3C,D), as well as a significant decrease in % BV/TV, Tb. N,
and an increase in trabecular separation, compared with control
mice (Fig. 3E–H). Importantly, osteolytic lesion development did
not occur at the injection site (ie, at the site where the needle
drilled into the bone); these results demonstrate that intrafe-
moral inoculation of 5TGM1-GFP induces extensive myeloma
bone disease in the localized 5TGM1 model.
Intrafemoral inoculation of myeloma cells induces pain-
like behaviors
To evaluate whether myeloma-induced bone disease in the
localized model would cause the development of pain-related
behaviors, mice were exposed to stimulus-evoked and non-stim-
ulus-evoked behavioral tests. Similar to the systemic model,
mechanical allodynia and thermal hyperalgesia were unchanged
in myeloma-bearing mice (Fig. 4A,B). However, non-stimulus-
evoked behavioral tests showed a reduction in burrowing
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Fig. 1. Legend on next page.
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capacity, as well as a decrease in limb use score in myeloma-
bearing mice, compared with their sham matched controls
(Fig. 4C,D).
Myeloma-bearing mice developed paraplegia approximately
3 to 4 weeks after cell inoculation, further confirming the disease
phenotype (Fig. 4E). To demonstrate that the behavioral out-
comes were caused by myeloma-induced bone pain and not
bymotor impairment as a consequence of disease development,
we evaluated the analgesic effect of morphine in this model
26 days after cell inoculation. The effect of systemic morphine,
at a dose comparable to that used for the treatment of cancer-
induced bone pain in murine models (10 mg/kg−1),(30) was
examined in the limb use test (Fig. 5A). Morphine treatment
improved the limb use scores ofmyeloma-bearing animals, dem-
onstrating that intrafemoral inoculation of myeloma cells
induces a pain-like phenotype, which is reversible by a clinically
relevant opioid (Fig. 5B).
Bisphosphonates prevent myeloma bone disease and
attenuate pain-like behaviors
To examine whether bone disease was the main driver of the
pain-like phenotype, myeloma-bearing mice were treated twice
a week with vehicle or zoledronic acid (125 μg/kg−1; Fig. 6A) as
previously described.(39) Biweekly bisphosphonate treatment
caused a significant attenuation of pain-like behavior over time
as assessed by the limb use test (Fig. 6B,C), as well as an increase
in survival rate (Fig 6D). Analysis of bone lesions showed that
biweekly bisphosphonate treatment effectively protects the
myeloma-bearing bones from developing osteolytic lesions
(Fig. 6E,F).
Intrafemoral inoculation of myeloma cells causes
denervation
To further ratify the disease phenotype, the presence of
5TGM1-GFP cells in the bone marrow of myeloma-inoculated
mice was evaluated by immunohistochemistry in decalcified
bone sections. GFP-positive cells were found extensively infiltrat-
ing the bone marrow of myeloma-bearing femurs, demonstrat-
ing tumor cell growth in this model (Fig. 7).
Moreover, to investigate whether tumor growth affected the
number and distribution of nerve fibers, broadly characterized
immunohistochemical markers for neuronal growth (GAP-43),
sensory (TH), and sympathetic (CGRP) neurons were assessed
by immunohistochemistry and laser confocal microscopy.
Although all three neuronal markers were detectable in the bone
marrow of femurs from shammice, myeloma-bearing femurs did
not display detectable staining, indicating complete denervation
of the bone marrow of these mouse bones. These results were
consistent and reproducible between experiments, and suggest
that myeloma growth induces bone marrow denervation in this
model (Fig. 7).
Discussion
Bone pain is a serious and debilitating symptom for MM
patients(12); however, it remains understudied and its causes are
unknown. Current therapies targeting cancer pain are based on
pain intensity(40) rather than its underlying mechanisms, leading
to analgesic treatments with low efficacy and unwanted side-
effects. Superior drugs targeting the disease-specific mechanisms
of bone pain are crucial to improve the quality of life of MM
patients. Here, we present an immunocompetent mouse model
of myeloma-induced bone pain and show that morphine reverses
its pain-like phenotype, suggesting its adequacy for pharmacolog-
ical testing of novel therapies. Additionally, we propose that
myeloma-induced bone pain is driven by the combinatorial effect
of osteolytic lesion development and bone marrow denervation.
Althoughmany preclinical models of MM are available,(36) cur-
rently only one study by Hiasa and colleagues(14) has addressed
pain-related behaviors, but their results are mainly based on a
xenograft myeloma model, which uses immunocompromised
mice. However, mounting evidence has shown that the immune
system plays a pivotal role in the transition from acute to chronic
pain,(41,42) suggesting that the validity of xenograft models is
compromised. In contrast, we investigated pain-related behav-
iors in the immunocompetent 5TGM1-GFP model, in which syn-
geneic myeloma cells are systemically administered in the tail
vein.(19) Although the disease phenotype in this model was con-
firmed by increased serum paraprotein, splenomegaly, tumor
development, and paralysis, pain-related behaviors were not
apparent in these mice. Additionally, significant bone disease
was not detected, in agreement with previous reports,(43) there-
fore highlighting that osteolysis is highly variable in this systemic
model.
We investigated a localized model of MM in which intrafe-
moral inoculation of 5TGM1-GFP cells in BKAL mice induces
quantifiable pain-related behavior and osteolytic lesions.
Mechanical and thermal thresholds were unchanged in
myeloma-bearing mice; however, it has previously been shown
that these tests might not be appropriate measures of deep tis-
sue pain such as bone pain.(44) Instead, more appropriate
approaches are tests that measure etiologically relevant behav-
iors indicative of well-being and pain-related behavior in
rodents,(45,46) such as burrowing and limb use. Using these tests,
we demonstrated the progressive development of a bone pain-
like phenotype in myeloma-bearing mice. Moreover, this pheno-
type could be reversed by a conventional opioid commonly used
in the clinic,(40) further demonstrating that these readouts are
measures of pain-related behavior rather than motor impair-
ment. Additionally, reversal of the pain-like phenotype by mor-
phine confirms the validity of this model for testing novel
analgesic drugs with translational potential.
Intrafemoral inoculation of 5TGM1 myeloma cells led to the
stable development of osteolytic lesions, similar to those found
FIGURE 1. The systemic 5TGM1model does not present pain-like behaviors (A) 5TGM1myeloma cells or vehicle was administered to BKALmice through
tail vein injection; thereafter, behavioral tests were conducted for 4 weeks. Upon euthanasia, hind limb bones were used to assess the presence of mye-
loma cells or of osteolytic lesions. (B) Pawwithdrawal threshold, as measured in the von Frey test, remained unchanged betweenmyeloma-bearing (n = 5)
and sham (n = 8) mice over time. (C) Paw withdrawal latency, measured in the hot plate test, of myeloma-bearing (n = 5) and sham (n = 8) mice was not
altered over time. (D,E) similar distance (D) and speed (E) moved in the locomotor test by myeloma-bearing (n = 5) and sham (n = 8) mice over time. (F)
Amount of sand burrowed by myeloma-bearing (n = 8) and sham (n = 9) mice over time. (G) Survival plot of myeloma-bearing (n = 5) and sham (n = 8)
mice, depicted as percentage of survival.
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Fig. 2. Systemic inoculation of 5TGM1 cells induces myeloma, but not osteolytic lesions. (A) Microscopic imaging of bone marrow flushes demonstrated
the presence of myeloma cells (green fluorescent protein- (GFP-) positive) in the long bones of 5TGM1-inoculated, but not sham, mice. Images were cap-
tured in a ZOE Fluorescence Cell Imager (objective 20×; bright field channel LED intensity 40 and exposure time 300 ms; green channel LED intensity
50 and exposure time 500 ms); image contrast was enhanced for better visualization of GFP-positive cells in ImageJ. Scale bars represent 100 μm. (B)
Quantification of GFP-positive cells in the bone marrow of right and left hind limbs of myeloma-bearing and sham mice (n = 8–10; ****p < 0.0001). (C)
Myeloma-bearing mice presented splenomegaly compared with sham mice (n = 8–10; ****p < 0.0001). (D) The concentration of serum paraprotein at
euthanasia was significantly higher in systemically inoculatedmyeloma-bearingmice than sham (n= 5–7; ***p < 0.001). (E) Three-dimensional μCT recon-
structions of the tibia of myeloma-bearing and shammice. (F) Myeloma-bearing mice did not present osteolytic lesions compared with sham. MM =mul-
tiple myeloma.
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Fig. 3. Intrafemoral inoculation of 5GTM1 cells induces osteolytic lesions. (A) 5TGM1myeloma cells or vehicle were inoculated in the medullary femoral cavity of
BKAL mice; thereafter, behavioral tests were conducted for the following 4 weeks. Upon euthanasia, mice were perfused and their femurs analyzed by μCT and
immunohistochemistry. (B) The concentration of serumparaprotein at euthanasia was significantly higher in intrafemorally inoculatedmyeloma-bearingmice than
in shammice (n = 6–7; ****p < 0.0001). (C) Three-dimensional μCT reconstructions of the femur of myeloma-bearing and shammice. Note the presence of osteo-
lytic lesions in myeloma-inoculated femurs. (D) Lesion area analyses of myeloma-bearing (n = 7) and sham (n = 5) femurs. (E) Three-dimensional reconstruction of
the trabecular bone of sham andmyeloma-bearing bones. (F) Myeloma bearing femurs (n = 8) presented decreased bone volume/total volume than sham bones
(n = 6; ***p < 0.001). (G) The trabecular number of myeloma-bearing femurs (n = 8) was significantly lower than that of sham femurs (n = 6; ****p < 0.0001).
(H) Myeloma-bearing femurs (n = 8) showed significantly higher trabecular separation than sham femurs (n = 6; ****p < 0.0001). MM = multiple myeloma.
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in the clinic.(47) Moreover, intrafemoral inoculation of myeloma
cells in BKAL mice led to the development of paraplegia approx-
imately 4 weeks after cell inoculation, indicating that the mye-
loma cells may have migrated to the vertebral bodies, leading
to spinal compression and consequent paraplegia, a well-
described feature of the disease in patients(5) that supports the
translational validity of this model. Although these mice showed
a significant increase in serum paraprotein, the paraprotein
levels were lower than those detected in the serum of
systemically inoculated mice. This is likely explained by the con-
fined tumor environment following the intrafemoral inoculation
of myeloma cells in this model, compared with the systemic one.
The effect of a common bisphosphonate, zoledronic acid, was
evaluated in the localized 5GTM1 model. Bisphosphonate treat-
ment is commonly used in the clinic to improve bone quality
and decrease skeletal-related events in myeloma patients, and
systematic literature reviews have shown that it ameliorates
pain(48,49) However, the quality of the pain data has recently
Fig. 4. The localized 5TGM1 model presents pain-like behaviors (A) Paw withdrawal threshold, as measured in the von Frey test, remained unchanged
between myeloma-bearing (n = 10) and sham (n = 6) mice over time. (B) Paw withdrawal latency, measured in the hot plate test, of myeloma-bearing
(n = 10) and sham (n = 6) mice was not altered over time. (C) Myeloma-bearing mice (n = 10) burrowed a significantly lower amount of sand compared
with sham (n = 6), 25 days after surgery (*p < 0.05). (D) The limb use score of myeloma-bearing mice (n = 10) decreased over time, compared with sham
(n = 6; *p < 0.05; **p < 0.01; ***p < 0.001) (E) Survival plot of myeloma-bearing (n = 10) and sham (n = 6) mice, depicted as percentage of survival. MM =
multiple myeloma.
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been questioned because of the different read-outs used in dif-
ferent trials and the lack of clinically significant analgesic effect
in double-blinded clinical trials.(50) In the localized 5TGM1 model,
systemic treatment with zoledronic acid protected the myeloma-
bearing bones from developing osteolytic lesions. Bisphosphonate
treatment also led to increased survival and partly ameliorated the
pain-like behavior over time, suggesting that osteolytic bone
lesions may play a role in pain development, but not be
entirely responsible for it. The fact that the localized MMmodel
displayed pain-like behaviors whereas the systemic model did
not, could thus be partially explained by the lack of osteolytic
lesion development in the latter. However, it should be consid-
ered that the systemic model may display nociception that
could not be detected with the battery of behavioral tests used
in this study.
Interestingly, complete denervation of the bone marrow of
myeloma-bearing femurs was consistently observed across
experiments demonstrating, for the first time, that myeloma
tumor growth induces damage of the sensory and sympathetic
nerves, possibly contributing to pain development through
injury-induced neuronal sensitization. Our results are in agreement
with previously published reports of bonemarrowdenervation in a
mouse model of osteosarcoma(51); here, sarcoma-inoculated mice
also showed a decrease in limb use scores that were accompanied
by multiple neurochemical changes in the cell bodies of the sen-
sory neurons, potentially as a consequence of tumor-induced bone
marrow denervation. Interestingly, the only available report
describing the sensory innervation of myeloma-bearing femurs
shows neuronal sprouting(14) parallel to disease development,
which has also been described in other models of cancer-induced
bone pain.(52,53) Although it cannot be ruled out that myeloma-
inoculated mice also presented nerve sprouting prior to spinal
compression and paraplegia development, our results suggest that
pain-related behaviors were present during the last 4 to 5 experi-
mental days, suggesting that the denervation process had already
been initiated in parallel to the development of pain-related
behavior. Importantly, we report the first evidence of denervation
in myeloma-bearing bones, suggesting unstudied mechanisms
that require further attention. As systemic administration of the
same cell line in BKAL mice did not cause pain-related behaviors,
Fig. 5. Systemic morphine reverses pain-like behaviors in the localized 5TGM1model. (A) Myeloma-bearing and shammice were assessed in the limb use
test, 26 days after surgery. Thereafter, all animals received i.p. saline and their limb use score was assessed in the following 30, 60, and 120 min. After
4 hours from the last assessment, the limb use was again scored and all animals received i.p. morphine (10 mg/kg). The limb use test was then conducted
30, 60, and 120 min after morphine administration. (B) Myeloma-bearing mice showed a significant increase in limb use scores 30, 60, and 120 min after
morphine administration, compared with vehicle (n = 5–6; *p < 0.05, **p < 0.01). MM = multiple myeloma.
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Fig. 6. Bisphosphonatespreventmyelomabonediseaseandhaveananalgesiceffecton the localized5TGM1model. (A) 5TGM1myelomacellsorvehiclewere inoc-
ulated in themedullary femoral cavity of BKALmice; thereafter, behavioral testswere conducted for the following 30 days. Animalswere dosedwith vehicle or zole-
dronic acid (125 μg/kg−1) on postsurgical days 3, 7, 10, 14, 17, 21, 24, and28. (B,C)myeloma-bearingmice (n=7) treatedbiweeklywith zoledronic acid (125 μg kg−1)
showedanameliorationofpain-likebehavior, comparedwithvehicle-treated,myeloma-bearingmice (n=8).Bothgroups showedsignificantpain-likebehaviorcom-
paredwith sham-operatedmice (n= 4; *p < 0.05, ****p < 0.0001). (D) Bisphosphonate-treated, myeloma-bearingmice showed increased survival comparedwith
vehicle-treated,myeloma-bearingmice. (E)Myeloma-bearing, bisphosphonate-treated femurs (n=7), like sham (n=4), presented significantly less osteolytic lesions
thatmyeloma-bearing,vehicle-treatedfemurs(n=7;****p < 0.0001). (F)Three-dimensionalμCTreconstructionsofthefemurofshamandmyeloma-bearing,vehicle-
or bisphosphonate-treated femurs. MM + veh =Myeloma-bearing, vehicle-treatedMM + ZOL=myeloma-bearing, zoledronic acid-treated.
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we suggest that myeloma-induced bone pain is the result of com-
binatorial mechanisms including osteolytic lesion development
and bone marrow denervation, and that multitarget drugs may
be needed for its effective treatment.
Developing optimal preclinical models for the study of dis-
ease mechanisms is of primary importance. Here, we present
the first in-depth characterization of an immunocompetent
model of myeloma-induced bone pain, which allows the eval-
uation of site-specific pain-related behavior through the use
of non-stimulus-evoked behavioral tests. Furthermore, intra-
femoral inoculation of myeloma cells induces the develop-
ment of osteolytic lesions and denervation of the tumor-
bearing bone in this model, suggesting that myeloma-
induced bone pain may be caused by a combination of osteo-
lytic bone lesions and myeloma-induced nerve damage. We
suggest that the intrafemoral 5TGM1 model is a useful tool
to further understand the mechanisms of myeloma bone dis-
ease and myeloma-induced bone pain, which is of foremost
Fig. 7. The localized 5TGM1 presents denervation of the bone marrow. Representative pictures of histological sections of myeloma-bearing and sham
femurs, stained for GFP (marker of myeloma cells, 5TGM1-GFP), GAP-43 (marked or nerve growth), TH (marker of sympathetic neurons), and CGRP (marker
of sensory neurons). In two independent experiments, myeloma-bearing femurs showed extensive denervation of the bone marrow compared with
sham. Images were captured in a Carl Zeiss scanning confocal laser microscope (model LSM800) with a Plan-Apochromat 63×/1.40 oil differential inter-
ference contrast (DIC) (working distance = 0.19 mm) objective and a numerical aperture of 1.4, at 23C. Images were taken with the X-stack function at an
interval of 1.00 μm with a Carl Zeiss model Axio Cam ICc5 camera, and the software Zen 2.3 blue edition system (Zeiss). The used fluorochromes were
Cy3-conjugated affiniPure donkey anti-rabbit IgG and Cy2-conjugated affinPure donkey anti-chicken IgG. Scale bars represent 20 μm.
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importance to improve the quality of life of multiple myeloma
patients.
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